Enanta Pharmaceuticals Inc (ENTA)
15.22
+1.30
(+9.38%)
USD |
NASDAQ |
May 03, 16:00
15.22
0.00 (0.00%)
After-Hours: 20:00
Enanta Pharmaceuticals Net Income (Quarterly): -33.41M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -33.41M |
| September 30, 2023 | -28.11M |
| June 30, 2023 | -39.06M |
| March 31, 2023 | -37.66M |
| December 31, 2022 | -28.99M |
| September 30, 2022 | -26.35M |
| June 30, 2022 | -31.70M |
| March 31, 2022 | -33.59M |
| December 31, 2021 | -30.12M |
| September 30, 2021 | -24.60M |
| June 30, 2021 | -24.02M |
| March 31, 2021 | -22.04M |
| December 31, 2020 | -8.328M |
| September 30, 2020 | -29.34M |
| June 30, 2020 | -14.26M |
| March 31, 2020 | -6.005M |
| December 31, 2019 | 13.44M |
| September 30, 2019 | 9.191M |
| June 30, 2019 | 7.036M |
| March 31, 2019 | 4.145M |
| December 31, 2018 | 26.01M |
| September 30, 2018 | 27.42M |
| June 30, 2018 | 20.29M |
| March 31, 2018 | 12.56M |
| December 31, 2017 | 11.69M |
| Date | Value |
|---|---|
| September 30, 2017 | 36.51M |
| June 30, 2017 | -8.426M |
| March 31, 2017 | -5.392M |
| December 31, 2016 | -4.98M |
| September 30, 2016 | -1.802M |
| June 30, 2016 | -1.076M |
| March 31, 2016 | -1.645M |
| December 31, 2015 | 26.19M |
| September 30, 2015 | 5.812M |
| June 30, 2015 | 2.418M |
| March 31, 2015 | 28.75M |
| December 31, 2014 | 42.01M |
| September 30, 2014 | -5.042M |
| June 30, 2014 | 50.05M |
| March 31, 2014 | -5.203M |
| December 31, 2013 | -5.37M |
| September 30, 2013 | -4.443M |
| June 30, 2013 | -4.138M |
| March 31, 2013 | -3.749M |
| December 31, 2012 | 21.96M |
| September 30, 2012 | -4.052M |
| June 30, 2012 | -3.501M |
| March 31, 2012 | 32.11M |
| December 31, 2011 | -3.159M |
| September 30, 2011 | -3.989M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-39.06M
Minimum
Jun 2023
13.44M
Maximum
Dec 2019
-20.42M
Average
-26.35M
Median
Sep 2022
Net Income (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -112.19M |
| Galectin Therapeutics Inc | -9.997M |
| Viking Therapeutics Inc | -27.36M |
| Akero Therapeutics Inc | -55.19M |
| 89bio Inc | -40.24M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 18.00M |
| Total Expenses (Quarterly) | 52.89M |
| EPS Diluted (Quarterly) | -1.58 |
| Enterprise Value | -42.87M |
| Profit Margin (Quarterly) | -185.6% |
| Earnings Yield | -43.12% |
| Normalized Earnings Yield | -43.12 |